RNAi & siRNA Licensing Deal Benchmarks
Market Analysis
RNA interference therapeutics have matured into a validated modality with multiple approved products and a deep clinical pipeline. Phase 2 RNAi/siRNA deals achieve a median total deal value of $1.6B, with upfront payments ranging from $141M to $393M. The Alnylam platform validation and GalNAc-conjugate delivery revolution have transformed RNAi from a struggling modality into a predictable, scalable drug development engine.
Milestone allocations for RNAi deals are balanced across development ($338M), regulatory ($541M), and commercial ($474M) categories. The overall deal structure follows an approximately 16% upfront / 84% milestone split, reflecting the de-risked delivery platform and well-characterized pharmacology.
Royalty rates for RNAi licensing transactions range from 11.7% to 19.2% at the base tier, escalating to 15.7%-23.2% on blockbuster sales. Key value drivers include the target gene, delivery technology (GalNAc vs. LNP), durability of knockdown, and potential for subcutaneous self-administration.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the average upfront payment for an RNAi/siRNA licensing deal?
How do RNAi deal terms compare to antisense oligonucleotide (ASO) deals?
What factors drive RNAi deal premiums?
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating